In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
|Videos|August 24, 2017
Treat-to-Target in Rheumatoid Arthritis
Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.
Advertisement
Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.
Advertisement
Related to this article
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
2
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
3
Pharmacists Positioned as Key Educators as Monoclonal Antibodies Emerge as COVID-19 Immunization Option
4
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
5